Lindbrook Capital, LLC Arcellx, Inc. Transaction History
Lindbrook Capital, LLC
- $1.06 Billion
- Q1 2025
A detailed history of Lindbrook Capital, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 39 shares of ACLX stock, worth $2,492. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39
Previous 7
457.14%
Holding current value
$2,492
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ACLX
# of Institutions
214Shares Held
48.8MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$287 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$255 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$239 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$225 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$194 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.8B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...